MedPath

Radial Artery Puncture Hemostasis Study

Not Applicable
Completed
Conditions
Radial Artery Hemostasis
Interventions
Device: Radial artery hemostasis
Registration Number
NCT04857385
Lead Sponsor
Semmelweis University Heart and Vascular Center
Brief Summary

RAPHE is an open label randomized clinical trial to assess physical, biological and chemical methods of radial artery puncture hemostasis following coronary catheterization.

A total of 600 subjects will be randomized in a 1:1:1 fashion to either the StatSeal, Axiostat or TR Band hemostasis devices.

Follow-up of the subject will take place 60 days after the index procedure.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Coronary angiogram planned from a radial artery approach
  • Use of 5, 6 or 7 French sheaths
Exclusion Criteria
  • Radial artery diameter <1.8 mm as measured via ultrasound
  • Established peripheral arterial disease
  • Known autoimmune illness
  • Hemodynamic instability
  • Pregnant or nursing
  • Condition following resuscitation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
StatSealRadial artery hemostasisPotassium-ferrate based chemical hemostasis device.
Terumo TR BandRadial artery hemostasisPhysical standard of care radial hemostasis device.
AxiostatRadial artery hemostasisChitosan based biological hemostasis device.
Primary Outcome Measures
NameTimeMethod
Radial artery fistula formation60 days (+/-10 days) post-procedure

Frequency of radial artery arteriovenous fistula formation after hemostasis

Radial artery bleeding60 days (+/-10 days) post-procedure

Bleeding from the radial artery puncture, classified via the EASY method

Radial artery occlusion60 days (+/-10 days) post-procedure

Frequency of radial artery occlusion after hemostasis

Radial artery (pseudo)aneurysm formation60 days (+/-10 days) post-procedure

Frequency of radial artery (pseudo)aneurysm formation after hemostasis

Secondary Outcome Measures
NameTimeMethod
Overall compression timeUp to 24 hours post-procedure

Overall time (in minutes) of device use as a hemostatis tool

Initial compression time of hemostatsis deviceUp to 30 minutes post-procedure

Initial time (in minutes) of the hemostasis device, needed to achieve primary patent hemostasis

Number of compression devices neededUp to 24 hours post-procedure

Overall number of compression devices needed for hemostatis

Trial Locations

Locations (3)

University of Szeged, Department of Invasive Cardiology

🇭🇺

Szeged, Csongád-Csanád, Hungary

Department of Cardiology and Cardiac Surgery

🇭🇺

Debrecen, Hajdú-Bihar, Hungary

Semmelweis University Heart and Vascular Center

🇭🇺

Budapest, Hungary

© Copyright 2025. All Rights Reserved by MedPath